Telix Prescription drugs Restricted (TLX) Presents at H.C. Wainwright twenty seventh Annual International


Telix Prescription drugs Restricted (NASDAQ:TLX) H.C. Wainwright twenty seventh Annual International Funding Convention September 9, 2025 12:00 PM EDT

Firm Individuals

Christian Behrenbruch – Co-Founder, MD, Group CEO & Government Director

Convention Name Individuals

Robert Burns – H.C. Wainwright & Co, LLC, Analysis Division

Presentation

Robert Burns
Managing Director & Senior Healthcare Analyst

Welcome to our subsequent fireplace chat. I am Robert Burns, Managing Director and Senior Biotech Analyst, H.C. Wainwright. And I’m joined as we speak by Christian Behrenbruch, the CEO of Telix Prescription drugs. Christian, thanks for becoming a member of us as we speak.

Christian Behrenbruch
Co-Founder, MD, Group CEO & Government Director

Sure. Thanks for the chance.

Query-and-Reply Session

Robert Burns
H.C. Wainwright & Co, LLC, Analysis Division

So one of many issues that I first needed to start out off with was clearly, Telix has skilled fast development and transformation through the years. So are you able to share a few of the key components which have contributed to the success?

Christian Behrenbruch
Co-Founder, MD, Group CEO & Government Director

Effectively, I feel the corporate is simply actually keen about radiopharmaceuticals. I feel one of many distinctive facets in regards to the firm is we do not actually consider in isotope platforms, proper? We expect that whenever you develop a radiopharmaceutical, you need to have a look at the scientific utility that you simply need to clear up.

It is best to take into consideration what pharmacophore achieves your organic goals finest. After which you need to select the appropriate isotope for the job. And so one of many issues that I feel is admittedly particular in regards to the firm, and it is mirrored within the infrastructure that we have constructed over the past — virtually — firm is sort of 10 years outdated, 8 years as a public firm is that agnosticism.

We would like a — we’re very — we’re a pure-play radio pharma firm. We consider that precision drugs is admittedly essential. That is form of one thing that is not



Source link

Related articles

Solana and Ethereum can coexist in tokenization race: Dragonfly

Solana and Ethereum will each thrive within the tokenization race and neither blockchain will push the opposite out of the area, says Dragonfly common associate Rob Hadick.“They're each Fb,” Hadick instructed CNBC’s “Squawk...

Nvidia agrees to a licensing cope with Groq; CEO Jonathan Ross and different prime executives will be part of Nvidia; Groq says it is...

Featured Podcasts Massive Expertise Podcast: 2025 In Overview, 2026 Predictions — With Reed Albergotti The Massive Expertise Podcast takes you behind the scenes within the tech world that includes interviews with plugged-in insiders and out of...

“AI Highlights Present Issues and Makes Them Larger”: Perception at FMLS:25 on Knowledge Challenges

Exness Dealer Assessment 2025: Regulation, Platforms & Buying and selling Situations Defined | Finance Magnates Exness Dealer Assessment 2025:...

Transferring Averages: Execs & Cons – Analytics & Forecasts – 24 December 2025

The Transferring Common (MA) is a cornerstone of technical evaluation. It smooths value information over a set interval, serving to merchants spot traits...

Power Switch: A Well timed Reset For The Power Play That is Left Behind (NYSE:ET)

This text was written byObserveJR Analysis is an opportunistic investor. He was acknowledged by TipRanks as a High Analyst. He was additionally acknowledged by In search of Alpha as a "High Analyst To...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com